| A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma JW Kjeldsen, CL Lorentzen, E Martinenaite, E Ellebaek, M Donia, ... Nature medicine 27 (12), 2212-2223, 2021 | 128 | 2021 |
| Arginase 1–based immune modulatory vaccines induce anticancer immunity and synergize with anti–PD-1 checkpoint blockade M Aaboe Jørgensen, S Ugel, M Linder Hübbe, M Carretta, M Perez-Penco, ... Cancer immunology research 9 (11), 1316-1326, 2021 | 38 | 2021 |
| Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic … J Handlos Grauslund, MO Holmström, NG Jørgensen, U Klausen, ... Frontiers in oncology 11, 637420, 2021 | 37 | 2021 |
| Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors SE Weis-Banke, M Lerdrup, D Kleine-Kohlbrecher, F Mohammad, S Sidoli, ... Cancer research 80 (17), 3466-3479, 2020 | 37 | 2020 |
| TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer M Perez-Penco, SE Weis-Banke, A Schina, M Siersbæk, ML Hübbe, ... Journal for immunotherapy of cancer 10 (12), 2022 | 22 | 2022 |
| The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines SE Weis-Banke, ML Hübbe, MO Holmström, MA Jørgensen, SK Bendtsen, ... Oncoimmunology 9 (1), 1771142, 2020 | 22 | 2020 |
| Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope E Martinenaite, SM Ahmad, SK Bendtsen, MA Jørgensen, SE Weis-Banke, ... Cancer Immunology, Immunotherapy 68, 1901-1907, 2019 | 22 | 2019 |
| Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner MO Holmström, REJ Mortensen, AM Pavlidis, E Martinenaite, ... Cellular & Molecular Immunology 18 (2), 415-426, 2021 | 15 | 2021 |
| Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment SK Bendtsen, M Perez-Penco, ML Hübbe, E Martinenaite, ... Oncoimmunology 11 (1), 2026020, 2022 | 10 | 2022 |
| Arginase 1-based immune modulatory vaccines induce anticancer immunity and synergize with anti-PD-1 checkpoint blockade. Cancer Immunol Res. 2021; 9 (11): 1316–1326. doi: 10 … M Aaboe Jørgensen, S Ugel, M Linder Hübbe, M Carretta, M Perez-Penco, ... Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder …, 0 | 10 | |
| Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells SE Weis-Banke, TL Lisle, M Perez-Penco, A Schina, ML Hübbe, ... Journal for immunotherapy of cancer 10 (10), 2022 | 3 | 2022 |
| An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma U Klausen, N Grønne Dahlager Jørgensen, JH Grauslund, ... OncoImmunology 10 (1), 1975889, 2021 | 3 | 2021 |
| A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma (vol 27, pg 2212, 2021) JW Kjeldsen, CL Lorentzen, E Martinenaite, E Ellebaek, M Donia, ... NATURE MEDICINE 28 (4), 871-871, 2022 | 1 | 2022 |
| Author correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma JW Kjeldsen, CL Lorentzen, E Martinenaite, E Ellebaek, M Donia, ... Nature Medicine 28 (4), 871, 2022 | 1 | 2022 |
| Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV U Klausen, JH Grauslund, NGD Jørgensen, SM Ahmad, M Jonassen, ... Frontiers in Oncology 12, 1023015, 2022 | | 2022 |
| Arginase-2 as a target for cancer immune therapy SE Weis-Banke University of Copenhagen, 2022 | | 2022 |
| 778 Modulating tumor microenvironment with arginase-1 specific T cells E Martinenaite, MA Jørgensen, REJ Mortensen, SM Ahmad, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | | 2021 |
| P04. 05 Modulating tumor microenvironment with arginase-1 specific T cells E Martinenaite, MA Joergensen, REJ Mortensen, SM Ahmad, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 2), 2020 | | 2020 |
